Medical Editor: John P. Cunha, DO, FACOEP
Nuromax (doxacurium chloride) Injection is a long-acting, nondepolarizing skeletal muscle relaxant used to provide skeletal muscle relaxation as an adjunct to general anesthesia, for endotracheal intubation, or to facilitate mechanical ventilation. The brand name of this medication is discontinued, but generic versions may be available. Common side effects of Nuromax (doxacurium chloride) include:
- injection site reactions
- double vision
- prolonged drug effects such as weakness or skeletal muscle paralysis, and
- allergic reactions (including anaphylaxis)
Dosage of Nuromax is determined by your physician and the drug is administered intravenously. Nuromax may interact with isoflurane, enflurane, halothane, antibiotics, magnesium salts, lithium, local anesthetics, procainamide, quinidine, phenytoin, or carbamazepine. Tell your doctor all medications and supplements you use. During pregnancy, Nuromax should be used only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Our Nuromax (doxacurium chloride) Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
The most frequent adverse effect of nondepolarizing blocking agents as a class consists of an extension of the pharmacological action beyond the time needed for surgery and anesthesia. This effect may vary from skeletal muscle weakness to profound and prolonged skeletal muscle paralysis resulting in respiratory insufficiency and apnea which require manual or mechanical ventilation until recovery is judged to be clinically adequate (see OVERDOSAGE). Inadequate reversal of neuromuscular block from NUROMAX (doxacurium chloride) is possible, as with all nondepolarizing agents. Prolonged neuromuscular block and inadequate reversal may lead to postoperative complications.
Observed in Clinical Trials
Adverse experiences were uncommon among the 1034 surgical patients and volunteers who received NUROMAX (doxacurium chloride) and other drugs in US clinical studies in the course of a wide variety of procedures conducted during balanced or inhalational anesthesia. The following adverse experiences were reported in patients administered NUROMAX (doxacurium chloride) (all events judged by investigators during the clinical trials to have a possible causal relationship):
Incidence Greater than 1%
Incidence Less than 1%
|Cardiovascular:*||Hypotension,† flushing,† ventricular fibrillation, myocardial infarction|
|Dermatological:||Urticaria, injection site reaction|
|Nonspecific:||Difficult neuromuscular block reversal, prolonged drug effect, fever|
|* Reports of ventricular fibrillation (n
= 1) and myocardial infarction (n = 1) were limited to ASA Class 3-4 patients
undergoing cardiac surgery (n = 142).
† 0.3% incidence. All other reactions unmarked were ≤ 0.1%.
Observed During Clinical Practice
There have been post-marketing reports of severe allergic reactions (anaphylactic and anaphylactoid reactions) with the use of neuromuscular blocking agents of which NUROMAX (doxacurium chloride) is a member. These reactions, in some cases, have been life threatening and fatal. Because these reactions were reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency (see WARNINGS and PRECAUTIONS).
Read the entire FDA prescribing information for Nuromax (Doxacurium Chloride)
© Nuromax Patient Information is supplied by Cerner Multum, Inc. and Nuromax Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.